Literature DB >> 17100982

Fecal calprotectin in first-degree relatives of patients with ulcerative colitis.

Massimo Montalto1, Valentina Curigliano, Luca Santoro, Alessandro Armuzzi, Giovanni Cammarota, Marcello Covino, Maria C Mentella, Francesca Ancarani, Raffaele Manna, Antonio Gasbarrini, Giovanni Gasbarrini.   

Abstract

OBJECTIVES: The pathogenesis of inflammatory bowel disease seems to depend on the combination of genetic and environmental factors. To evaluate genetic susceptibility, one approach is to search for specific markers in apparently unaffected family members of patients. Our aim was to evaluate fecal calprotectin concentrations (FCCs) in first-degree relatives of patients with ulcerative colitis (UC). PATIENTS: Fifty-five patients with UC and 167 healthy first-degree relatives were recruited; 38 of the patients' spouses were also enrolled. One hundred fifty healthy subjects participated as the control group.
METHODS: FCCs were determined by ELISA. FCCs were compared among the groups by Kruskal-Wallis analysis of variance (ANOVA) test followed by Mann-Whitney U test.
RESULTS: Significantly greater FCCs were found in first-degree relatives of patients with UC (76.0 [34.7-129.6] microg/g) as compared with controls (31.6 [17.0-45.0]) (P < 0.0001). Fecal calprotectin levels in patients with UC (256.0 [153.0-356.0] microg/g) were significantly higher as compared with first-degree relatives, spouses (43.8 [18.6-89.0] microg/g), and controls (P < 0.0001 for all comparisons). FCC of relatives was significantly higher than FCC of spouses (P = 0.01). FCC of spouses had a significantly higher FCC with respect to controls (P = 0.01).
CONCLUSIONS: First-degree relatives of patients with UC had greater FCC values and could have a subclinical intestinal inflammation. It needs to be clarified if this finding is the consequence of genetic predisposition, of environmental factors, or the interaction of both, and if relatives with high FCC have a greater risk of developing the disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17100982     DOI: 10.1111/j.1572-0241.2006.00884.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  8 in total

1.  Can chronic gastritis cause an increase in fecal calprotectin concentrations?

Authors:  Massimo Montalto; Antonella Gallo; Gianluca Ianiro; Luca Santoro; Ferruccio D'Onofrio; Riccardo Ricci; Giovanni Cammarota; Marcello Covino; Monica Vastola; Antonio Gasbarrini; Giovanni Gasbarrini
Journal:  World J Gastroenterol       Date:  2010-07-21       Impact factor: 5.742

2.  Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes.

Authors:  Andrea Vieira; Chia Bin Fang; Ernani Geraldo Rolim; Wilmar Artur Klug; Flávio Steinwurz; Lucio Giovanni Battista Rossini; Paulo Azevedo Candelária
Journal:  BMC Res Notes       Date:  2009-10-29

3.  Non-invasive panel tests for gastrointestinal motility monitoring within the MARS-500 Project.

Authors:  Aldo Roda; Mara Mirasoli; Massimo Guardigli; Patrizia Simoni; Davide Festi; Boris Afonin; Galina Vasilyeva
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

4.  Synergistic effect of interleukin-10-receptor variants in a case of early-onset ulcerative colitis.

Authors:  Martina Galatola; Erasmo Miele; Caterina Strisciuglio; Lorella Paparo; Daniela Rega; Paolo Delrio; Francesca Duraturo; Massimo Martinelli; Giovanni Battista Rossi; Annamaria Staiano; Paola Izzo; Marina De Rosa
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

5.  A Disease-Associated Microbial and Metabolomics State in Relatives of Pediatric Inflammatory Bowel Disease Patients.

Authors:  Jonathan P Jacobs; Maryam Goudarzi; Namita Singh; Maomeng Tong; Ian H McHardy; Paul Ruegger; Miro Asadourian; Bo-Hyun Moon; Allyson Ayson; James Borneman; Dermot P B McGovern; Albert J Fornace; Jonathan Braun; Marla Dubinsky
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2016-07-02

Review 6.  Capturing the Biologic Onset of Inflammatory Bowel Diseases: Impact on Translational and Clinical Science.

Authors:  Dario Sorrentino; Vu Q Nguyen; Maithili V Chitnavis
Journal:  Cells       Date:  2019-06-06       Impact factor: 6.600

Review 7.  Familial and ethnic risk in inflammatory bowel disease.

Authors:  Maria Pia Costa Santos; Catarina Gomes; Joana Torres
Journal:  Ann Gastroenterol       Date:  2017-10-26

Review 8.  Mend Your Fences: The Epithelial Barrier and its Relationship With Mucosal Immunity in Inflammatory Bowel Disease.

Authors:  Eva Martini; Susanne M Krug; Britta Siegmund; Markus F Neurath; Christoph Becker
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2017-03-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.